Xie X, Shin Y, Kim T, Seong Y, Yi Y, Kim D
Am J Cancer Res. 2025; 15(1):113-126.
PMID: 39949939
PMC: 11815360.
DOI: 10.62347/RGZG2120.
Alafate W, Lv G, Zheng J, Cai H, Wu W, Yang Y
Cell Death Dis. 2024; 15(5):366.
PMID: 38806469
PMC: 11133443.
DOI: 10.1038/s41419-024-06735-1.
Zheng Z, Zhao Y, Yu H, Wang T, Li J, Xu L
Commun Biol. 2024; 7(1):18.
PMID: 38177713
PMC: 10767110.
DOI: 10.1038/s42003-023-05664-7.
Fan X, Guan G, Wang J, Jin M, Wang L, Duan X
Oncol Rep. 2023; 50(6).
PMID: 37859622
PMC: 10620845.
DOI: 10.3892/or.2023.8651.
Wei X, Png C, Weerasooriya M, Li H, Zhu C, Chen G
Immune Netw. 2023; 23(4):e34.
PMID: 37670811
PMC: 10475826.
DOI: 10.4110/in.2023.23.e34.
OSGIN1 is a novel TUBB3 regulator that promotes tumor progression and gefitinib resistance in non-small cell lung cancer.
Xie X, Laster K, Li J, Nie W, Yi Y, Liu K
Cell Mol Life Sci. 2023; 80(9):272.
PMID: 37646890
PMC: 11071769.
DOI: 10.1007/s00018-023-04931-4.
Transcriptome Analysis of the Inhibitory Effects of 20(S)-Protopanaxadiol on NCI-H1299 Non-Small Cell Lung Cancer Cells.
Cong Z, Zhang X, Lv Z, Jiang J, Wang L, Li J
Molecules. 2023; 28(15).
PMID: 37570716
PMC: 10421167.
DOI: 10.3390/molecules28155746.
Phosphatidic Acid Stimulates Lung Cancer Cell Migration through Interaction with the LPA1 Receptor and Subsequent Activation of MAP Kinases and STAT3.
Gomez-Larrauri A, Gangoiti P, Camacho L, Presa N, Martin C, Gomez-Munoz A
Biomedicines. 2023; 11(7).
PMID: 37509443
PMC: 10376810.
DOI: 10.3390/biomedicines11071804.
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield S
J Thorac Oncol. 2023; 18(9):1165-1183.
PMID: 37182602
PMC: 10524759.
DOI: 10.1016/j.jtho.2023.05.007.
Characterization of driver mutations in Chinese non-small cell lung cancer patients using a novel targeted sequencing panel.
Zhao J, Wu Y, Chen M, Xu Y, Zhong W, Wang M
J Thorac Dis. 2023; 14(12):4669-4684.
PMID: 36647494
PMC: 9840037.
DOI: 10.21037/jtd-22-909.
BCI, an inhibitor of the DUSP1 and DUSP6 dual specificity phosphatases, enhances P2X7 receptor expression in neuroblastoma cells.
Benito-Leon M, Gil-Redondo J, Perez-Sen R, Delicado E, Ortega F, Gomez-Villafuertes R
Front Cell Dev Biol. 2023; 10:1049566.
PMID: 36589747
PMC: 9797830.
DOI: 10.3389/fcell.2022.1049566.
NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells.
de Miranda L, Lima K, Coelho-Silva J, Traina F, Kobayashi S, Machado-Neto J
Sci Rep. 2022; 12(1):17092.
PMID: 36224313
PMC: 9556623.
DOI: 10.1038/s41598-022-21419-6.
GFAT1-linked TAB1 glutamylation sustains p38 MAPK activation and promotes lung cancer cell survival under glucose starvation.
Wei S, Zhao Q, Zheng K, Liu P, Sha N, Li Y
Cell Discov. 2022; 8(1):77.
PMID: 35945223
PMC: 9363421.
DOI: 10.1038/s41421-022-00423-0.
Functional Roles of JNK and p38 MAPK Signaling in Nasopharyngeal Carcinoma.
Pua L, Mai C, Chung F, Khoo A, Leong C, Lim W
Int J Mol Sci. 2022; 23(3).
PMID: 35163030
PMC: 8834850.
DOI: 10.3390/ijms23031108.
TR35 Exerts Anti-tumor Effects by Modulating Mitogen-Activated Protein Kinase and STAT3 Signaling in Lung Cancer Cells.
Shi Z, Gao Y, Feng L, Tian W, Dou Z, Liu C
Front Cell Dev Biol. 2021; 9:723346.
PMID: 34760885
PMC: 8573214.
DOI: 10.3389/fcell.2021.723346.
JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer.
Josue Ruiz E, Lan L, Diefenbacher M, Riising E, Da Costa C, Chakraborty A
JCI Insight. 2021; 6(13).
PMID: 34236045
PMC: 8410048.
DOI: 10.1172/jci.insight.124985.
Molluscan Compounds Provide Drug Leads for the Treatment and Prevention of Respiratory Disease.
Summer K, Browne J, Liu L, Benkendorff K
Mar Drugs. 2020; 18(11).
PMID: 33228163
PMC: 7699502.
DOI: 10.3390/md18110570.
Contribution of miRNAs, tRNAs and tRFs to Aberrant Signaling and Translation Deregulation in Lung Cancer.
Skeparnias I, Anastasakis D, Grafanaki K, Kyriakopoulos G, Alexopoulos P, Dougenis D
Cancers (Basel). 2020; 12(10).
PMID: 33092114
PMC: 7593945.
DOI: 10.3390/cancers12103056.
Inhibiting MAPK14 showed anti-prolactinoma effect.
Ding Q, Zhang Y, Ma L, Chen Y, Wu J, Zhang H
BMC Endocr Disord. 2020; 20(1):138.
PMID: 32894113
PMC: 7487756.
DOI: 10.1186/s12902-020-00619-z.
SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities.
Gupta I, Rizeq B, Elkord E, Vranic S, Moustafa A
Cancers (Basel). 2020; 12(8).
PMID: 32764454
PMC: 7464614.
DOI: 10.3390/cancers12082186.